Cholesterol lowering API Industry: Global Industry Analysis and Forecast 2020 – 2027
Atorvastatin API Market Overview
The hypercholesterolemia segment is expected to
lead the market and register a substantial CAGR to reach USD 2,10,753.23
thousand by the end of 2023. High prevalence of hypercholesterolemia is expected
to drive the market growth. Additionally, the segment is projected to exhibit
the highest CAGR of 4.09% from 2018 to 2023.
North America accounted for the largest market
share of 40.64% in 2017, and the regional market is projected to register a CAGR
of 3.10% during the forecast period. Asia-Pacific is expected to register the
fastest CAGR. The Chinese market is projected to exhibit the highest growth
rate of 5.86% during the forecast period from 2018 to 2023.
Request Free
Sample Copy at:
https://www.marketresearchfuture.com/sample_request/7730
Atorvastatin
API Market Segmentation
The
hypercholesterolemia segment is expected to lead the market and register a
substantial CAGR to reach USD 2,10,753.23 thousand by the end of 2023. High
prevalence of hypercholesterolemia is expected to drive the market growth.
Additionally, the segment is projected to exhibit the highest CAGR of 4.09%
from 2018 to 2023
Atorvastatin
API Market Regional Analysis
North America
accounted for the largest market share of 40.64% in 2017, and the regional
market is projected to register a CAGR of 3.10% during the forecast period.
Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected
to exhibit the highest growth rate of 5.86% during the forecast period from
2018 to 2023.
The European
market is estimated to exceed USD 1,31,094.04 thousand by 2023. High prevalence
of hypercholesterolemia and mixed dyslipidemia are driving the growth of the
Atorvastatin API market in the region. France is the major contributor to the
growth of the regional market, followed by the UK.
Atorvastatin
API Market Players
·
Globus Medical, Inc. (U.S.)
·
Depuy Synthes Inc. (Johnson & Johnson) (U.S.)
·
Smith & Nephew plc. (UK)
·
NuVasive, Inc. (U.S.)
·
Stryker Corporation (U.S.)
·
Integra LifeSciences Holdings Corporation (U.S.)
·
Zimmer Biomet Holdings, Inc. (U.S.)
·
Medtronic, plc (Ireland)
·
Wright Medical Group N.V. (Netherlands)
·
The Orthopedic Implant Company (U.S.)
·
Aesculap Implant Systems (U.S.)
·
Conmed Corporation (U.S.)
·
BioTek Instruments, Inc. (U.S.)
·
Arthrocare Corporation (U.S.)
among others
are some key companies in the global Atorvastatin API that are listed by MRFR
for market research.
Browse Detailed
TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/epilepsy-market-7730
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Comments
Post a Comment